Australia markets open in 8 minutes

Treace Medical Concepts, Inc. (TMCI)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
16.05+0.82 (+5.38%)
At close: 04:00PM EDT
16.05 0.00 (0.00%)
After hours: 04:01PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close15.23
Open15.45
Bid6.41 x 1000
Ask18.65 x 800
Day's range15.33 - 16.18
52-week range12.48 - 37.17
Volume133,652
Avg. volume229,414
Market cap887.226M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Treace Medical Concepts Reports First Quarter 2022 Financial Results

    PONTE VEDRA, Fla., May 05, 2022 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions), today reported financial results for the first quarter ended March 31, 2022. Recent Highlights: Revenue of $29.0 million in the first quarter 2022, a 55% increase over the same period last year.Gross margin of 81.0% in the first quarter 2022.F

  • GlobeNewswire

    Treace Announces Peer-Reviewed Publication of ALIGN3D™ Multicenter Prospective Clinical Data

    PONTE VEDRA, Fla., May 05, 2022 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace”) (Nasdaq: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ procedure, today announced the publication of a peer-reviewed manuscript that details an interim dataset of its ALIGN3D™ multicenter, prospective clinical study in the Journal of Foot & Ankle Surgery. Published interi

  • GlobeNewswire

    Treace Secures Up to $150 Million in Debt Financing

    PONTE VEDRA, Fla., May 02, 2022 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (Nasdaq: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions), today announced that it has entered into a new five-year $150 million loan arrangement with MidCap Financial, comprising up to $120 million in term loans and a $30 million revolving credit facility. Proceeds from the new term loan refinanced the